PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

High Disease Prevalence and Drug Patent Expiries Spearhead Growth in Indian Diabetes Therapeutics Finds Frost & Sullivan - Countless undiagnosed cases point to a large patient pool waiting to be tapped for education, early diagnosis, and therapy - Healthcare.Frost.com
High Disease Prevalence and Drug Patent Expiries Spearhead Growth in Indian Diabetes Therapeutics Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Mumbai, India, 2012/11/26 - Countless undiagnosed cases point to a large patient pool waiting to be tapped for education, early diagnosis, and therapy - Healthcare.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

With diabetes in India reaching epidemic proportions, the related therapeutics market is expected to grow at a double digit rate over the next 5 years. Higher disposable incomes have raised the incidence of this lifestyle disease, turning India into the world’s diabetic capital. Enhanced diagnostics will further broaden the patient base, and pharmaceutical companies that offer drugs with better efficacy and affordability will fare well in the market.

New analysis from Frost & Sullivan (healthcare.frost.com), Overview of the Diabetes Therapeutics Market in India, estimates the market revenues to reach $1.49 billion by 2016.

Rapid cultural changes, such as increasing urbanization, modified diet patterns, and sedentary lifestyles among the younger generation, have heightened the prevalence of diabetes in India. With a rapidly expanding segment of aging people, the treatment pool for type 2 cases in particular is expected to grow, increasing uptake of non-insulin therapies.

"The market for new non-insulin and insulin therapies is gaining ground, as treatment outcomes improve," said the Frost & Sullivan Analyst. "Novel drugs such as incretin mimetics, glucagon-like peptide-1 (GLP-1) agonists, and dipeptidyl peptidase-IV (DPP-IV) inhibitors are also earning acceptance among physicians."

The patent expiries of several existing drugs will actuate the launch of their generic versions. Although consumption volumes of these diabetes medications are expected to rise, their lower costs will not make significant impact on market revenues.

To boost the adoption of new drug classes, educational programs for both physicians and patients are necessary. Only a small percentage of the Indian population fully understands the disease, and government initiatives, such as the National Program for the Prevention and Control of Diabetes, Cardiovascular Diseases, and Stroke (NPDCS), aim to increase this percentage.

"The Indian government has also held mass early detection screening programs in 100 districts and 33 cities," noted the analyst. "Patient compliance centres are addressing the challenges of expensive treatment, inconvenient modes of administration, and the unpleasant side effects of oral anti-diabetics. These initiatives will result in better diabetes management and increase patient share, fuelling growth in the therapeutics market."

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Caroline Lewis/ Akshata Mhatre, Corporate Communications, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.. Upon receipt of the above information, a brochure will be sent to you by email.

Overview of the Diabetes Therapeutics Market in India is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: Contract Research and Manufacturing Services Market in India, Clinical Research Organization Market in India, Vaccine Market in India and GCC Pharmaceutical Market, All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Overview of the Diabetes Therapeutics Market in India / P585-52

Contact:
Nimisha Iyer
Corporate Communications – South Asia, Middle East and North Africa
P: +91 98200 50519 - E: niyer[.]frost.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


High Disease Prevalence and Drug Patent Expiries Spearhead Growth in Indian Diabetes Therapeutics Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Caroline Lewis / Akshata Mhatre - Frost.com 
+91 98217 37935 / +91 22 6607 2020 caroline.lewis[.]frost.com / akshatam[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)